; (B) is exempt from the provisions of section 505 of such Act relating to new drugs because— (i) the substance is intended solely for investigational use as described in section 505(i) of such Act; and (ii) the substance is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application; or (C) is the subject of a nonclinical drug investigation by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs. (3) Listing Not later than 180 days after the date of enactment of the Modernizing Drug Enforcement Act of 2018 , the Attorney General shall update schedule I in accordance with paragraph (1). The Attorney General may list substances in schedule I pursuant to paragraph (1) without regard to the process and considerations that are otherwise applicable under this section for adding, removing, or transferring controlled substances to, from, or among the schedules under section 202. .